TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Olanzapine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of metastatic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Post-operative Discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post-operative Inability to Chew
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measured levels of cyclobenzaprine and norcyclobenzaprine in plasma and urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of the 3 formulations of TNX-102 SL Tablets at 2.8 mg
Endpoint domain: Adverse events/effects
Primary endpoint: AUC(0-48) for TAK-536 in Dry Syrup Cohort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for TAK-536 in Dry Syrup Cohort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-48) for TAK-536 in Granule Cohort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for TAK-536 in Granule Cohort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rabies Virus Neutralizing Antibody Geometric Mean Titers at Day 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Rabies Virus Neutralizing Antibody Titer >=0.2 IU/mL and >=0.5 IU/mL at Day 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Complete Virus Neutralization at Starting Dilution (1/5) at Day 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Western Ontario & McMaster Universities Osteoarthritis Index (WOMAC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Visual Analog Score for Pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Proportion of patients achieving SVR24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: control rate of hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Degree of Liver Fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Efavirenz Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate Memory Task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean PSA doubling time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Face swelling degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trismus degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of pathway of center of mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area covered by center of mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Velocity of center of mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of asymptomatic versus symptomatic AF recurrence > 3 months post-AF ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IVC dynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac output, stroke volume and E/e' echocardiographic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: New onset of hepatorenal syndrome (HRS) or acute kidney injury (AKI)
Endpoint domain: Adverse events/effects
Primary endpoint: Pleural effusion volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of estimated fetal weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of peri-implantitis as measured by probing depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of peri-implantitis as measured by erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of peri-implantitis as measured by radiographic bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of time run in minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of time in minutes of vigorous and moderate exercise in following week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under plasma concentration versus time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to the last measurable concentration [AUC0-last]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation of humoral immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Activation of cellular immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety (no adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy (reduction of at least one Baker Grade)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemically Verified Smoking Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint mobility assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detectable pimonidazole staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Adverse Events and Serious Adverse Events leading to study withdrawal
Endpoint domain: Adverse events/effects
Primary endpoint: Absorption of PET-CT F-18-FDG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absorption of PET-CT Ga-68-PSMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: hematologic laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: clinical chemistry laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Response
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in P1NP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in CTX levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of jaw osteonecrosis after tooth extraction
Endpoint domain: Adverse events/effects
Primary endpoint: Change of L-spine total BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity to percussion/palpation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time spent in 70-180mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Systolic blood pressure monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic blood pressure monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Graft-versus-leukemia (GVL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Accurate knowledge level of vaccination
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Full vaccination of children
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Effectiveness of Combigan and Cosopt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in weekly binge frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indicator of mother health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indicator of newborn health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of HIV transmission
Endpoint domain: Mortality/survival
Primary endpoint: Bioavailability of Nilotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of lung ultrasound examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased platelet density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants Who Experienced Treatment-related Dose Limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Median Time To Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline-adjusted beta-cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Subjects With an Immune Response Against Diphtheria, Tetanus and Pertussis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients with gBRCA and sBRCA mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Insulin sensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent change in proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pocket Probing Depth (PPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrabony component (INTRA) of the defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity measured in steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in oxidised-LDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fMRI bold signal response during robotic manipulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity to the induction bodily illusions of Presence Hallucination
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sensitivity to Passivity experiences, loss of agency, and control questions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Efficacy of Blood product ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Medication Possession Ratio
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in depressive rumination
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the Plasma Concentration-Time Curve (AUC0-t) of L-Praziquantel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of L-Praziquantel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brian temperatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure-derived collateral flow index (CFIp)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Time interval between first notice of a suspect mole and definitive diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of participants without disease progression or death
Endpoint domain: Mortality/survival
Primary endpoint: Reach target of ≥ 2x10^6 CD34+ cells/kg within 2 days of apheresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: T2* measurement in cortex and basal ganglia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative incidence of nausea and/or vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Intraoperative cardiac index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma level of sodium nitrite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Physical component score (PSC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in the Mental component score (MCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Composite Cardiovascular Morbidity or Mortality Event
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients who failed to get HCV RNA test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of HCV-RNA positivity among patients with anti-HCV antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of HCV-RNA positivity linkage to care
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sedation assessment using Richmond Agitation and Sedation Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesia evaluation using digital pain scoring method
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesia evaluation using Critical-Care Pain Observation Tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological diagnosis of gallbladder polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ARFI AUC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful rate of one-time catheterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Occurrence of major adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of unplanned stay in critical/intensive care unit
Endpoint domain: Adverse events/effects
Primary endpoint: Compliance to Tertiary Care Follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in renal and cerebral regional oxygenation (rSO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Appearance of Anti-HBe
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of skin breaks
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Events (AE), Serious Adverse Events (SAE), Adverse Events of Special Interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of Vitamin E
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change from OMERACT-EULAR composite PDUS synovitis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abundance of colony forming units of Staphylococcus aureus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in mixed urinary incontinence symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in urinary distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in overactive bladder satisfaction with treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in urinary tract condition severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in urinary tract condition improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in sexual quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: number with dyslipidemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Immune state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patterns of metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Arterial pressure measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Biomarker NT-proBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Reported Device-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Psychiatric illness assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metacognition assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Narrative coherence assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: INR Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RBC Transfusion Units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: rebleeding rate within 14 days
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrence and metastasis
Endpoint domain: Mortality/survival
Primary endpoint: percent change in FENO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Crying Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of voruciclib
Endpoint domain: Adverse events/effects
Primary endpoint: Change in global cognitive function by the Alzheimer's Disease Assessment Scale (ADAS-Cog)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in global cognitive function by the Montreal Cognitive Assessment (MoCA)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Occurrence of pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Time to development of persistent AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urethro-cutaneous fistula occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Patient Specific Functional Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Neuropsychological evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eye tracking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood sampling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of radioactive dose recovered in urine and faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite endpoint of Death, MI, and ischemia-driven TVR
Endpoint domain: Mortality/survival
Primary endpoint: Disease remission based on PUCAI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in IMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: TESA and TESE outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Event free survival in controls
Endpoint domain: Mortality/survival
Primary endpoint: Neuropsychological functions: Continuous Performance Test (CPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychological functions: Cambridge Neuropsychological Test Automated Batteries (CANTAB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structural neuroimaging: Diffusing spectrum imaging (DSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional connectivity: Single-echo (SE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multi-echo (ME) Resting-state fMRI (rsfMRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of airway inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Monthly therapeutic paracentesis frequency
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Relative levels of Stat4a and Stat4β isoforms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of 18F-PSMA PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration (Cmax, tmax, AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in serum haemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in retinol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Initiation of underage drinking
Endpoint domain: Adverse events/effects
Primary endpoint: Distance Visual Acuities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes